# US 2009/0253125 A9 · Denaturat stable and/or protease resistant, chaperone-like oligomeric proteins, polynucleotides encoding same, their uses and methods of increasing a specific activity thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0253125 A9
- Document ID: US20090253125A9
- Status: Published application
- Kind: A9
- Application number: 10/526,445
- Filed: 2003-09-02
- Published: 2009-10-08
- Earliest claimed: 2001-03-05
- Inventors: Wangxia Wang; Dan Pelah; Tal Alergand
- Web page: https://patentgrep.com/patent/US20090253125A9

## CPC

- C07K 14/415: from plants
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07K 16/16: against material from plants
- C12N 9/96: Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
- C12N 15/8257: {for the production of primary gene products, e.g. pharmaceutical products, interferon}
- C12N 15/8273: {for drought, cold, salt resistance}
- C12P 21/02: having a known sequence of two or more amino acids, e.g. glutathione
- C07K 2319/20: containing a tag with affinity for a non-protein ligand
- C07K 2319/35: containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}

## Abstract

Novel denaturant-stable, protease resistant, homo-oligomeric proteins, also referred to herein as stable proteins (SPs), having chaperone-like activity; methods of production and purification of SPs; nucleic acids encoding SPs; methods of isolating nucleic acids encoding SPs; antibodies recognizing SPs; the use of SPs for stabilizing, refolding, repairing, preventing aggregation and de-aggregating macromolecules such as proteins; fusion proteins including SPs; nucleic acid constructs encoding the fusion proteins; and their uses in a variety of methods and applications.

## Claims

### Claim at position 1

1-113. (canceled)

### Claim 114

An isolated denaturant stable and/or protease resistant protein having chaperone-like activity having an HRP protection activity, as determined using an HRP protection assay, of at lest 10 Units/mg protein, wherein said HRP protection assay comprises nixing the isolated denaturant stable and/or protease resistant protein having chaperone-like activity at different final protein concentrations at a predetermined volume with 100 μl of 5 nM HRP present in 40 mM HEPES buffer at pH 7.5, thus forming a first reaction mixture, and following incubation of said reaction mixture at 25° C. for 16 hours, determining HRP remaining enzymatic activity by mixing 5 μl of said first reaction mixture with 100 μl of 3 3′ 5 5′tetramethylbenzidiine, thus forming a second reaction mixture, incubating said second reaction mixture for 10 minutes, stopping a reaction of said second reaction mixture by an addition of 100 μl of 1 M sulfuric acid and recording colorimetric change in said second reaction mixture at 435 nm, whereby said units are defined as a dilution factor of said denaturant stable and/or protease resistant protein having chaperone-like activity at a concentration of 1 mg/ml that confers 50% protection of HRP activity in said HRP protection assay.

### Claim 115 (depends on 114)

The isolated denaturant stable and/or protease resistant protein of claim 114, wherein said HRP protection activity is of at lest 500 Units/mg protein.

### Claim 116 (depends on 114)

The isolated denaturant stable and/or protease resistant protein of claim 114, wherein said HRP protection activity is of at lest 1000 Units/mg protein.

### Claim 117 (depends on 114)

The isolated denaturant stable and/or protease resistant protein of claim 114, wherein said HRP protection activity is of at lest 1500 Units/mg protein.

### Claim 118 (depends on 114)

The isolated denaturant stable and/or protease resistant protein of claim 114, wherein said HRP protection activity is of at lest 2000 Units/mg protein.

### Claim 119 (depends on 114)

The isolated denaturant stable and/or protease resistant protein of claim 114, wherein said HRP protection activity is of at lest 2500 Units/mg protein.

### Claim 120 (depends on 114)

The isolated denaturant stable and/or protease resistant protein of claim 114, wherein said HRP protection activity is of at lest 3000 Units/mg protein.

### Claim 121 (depends on 114)

The isolated denaturant stable and/or protease resistant protein of claim 114, wherein said HRP protection activity is of at lest 3500 Units/mg protein.

### Claim 122 (depends on 114)

The isolated denaturant stable and/or protease resistant protein of claim 114, wherein said HRP protection activity is of at lest 4000 Units/mg protein.

### Claim 123 (depends on 114)

The isolated denaturant stable and/or protease resistant protein of claim 114, wherein said HRP protection activity is of at lest 4500 Units/mg protein.

### Claim 124 (depends on 114)

The isolated denaturant stable and/or protease resistant protein of claim 114, wherein said HRP protection activity is of at lest 5000 Units/mg protein.

### Claim 125 (depends on 114)

The isolated denaturant stable and/or protease resistant protein of claim 114, wherein said HRP protection activity is of at lest 5500 Units/mg protein.

### Claim 126 (depends on 114)

The isolated denaturant stable and/or protease resistant protein of claim 114, wherein said HRP protection activity is of at lest 6000 Units/mg protein.

### Claim 127 (depends on 114)

The isolated denaturant stable and/or protease resistant protein of claim 114, wherein said HRP protection activity is of at lest 8000 Units/mg protein.

### Claim 128 (depends on 114)

The isolated denaturant stable and/or protease resistant protein of claim 114, wherein said HRP protection activity is of at lest 10000 Units/mg protein.

### Claim 129 (depends on 114)

The isolated denaturant stable and/or protease resistant protein of claim 114, wherein said HRP protection activity is of at lest 15000 Units/mg protein.

### Claim 130

A method of increasing a specific activity of a pre-isolated denaturant stable and/or protease resistant protein having chaperone-like activity as determined in Units of protecting activity per mg protein, the method comprising autoclaving said pre-isolated denaturant stable and/or protease resistant protein.

### Claim 131

A method of increasing a specific activity of a pre-isolated denaturant stable and/or protease resistant protein having chaperone-like activity as determined in Units of protecting activity per mg protein, the method comprising treating said pre-isolated denaturant stable and/or protease resistant protein with a protease.
